Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9422718 | Brain Research Protocols | 2005 | 4 Pages |
Abstract
γ-hydroxybutyric acid (GHB) and its precursors, 1,4-butanediol (1,4-BD) and γ-butyrolactone (GBL), are recreational drugs widely abused in the US, Europe and Australasia. A severe withdrawal syndrome from GHB, 1,4-BD and GBL has been increasingly documented over the last years, necessitating the development of a reliable animal model for investigations of potential therapeutic approaches. The present study describes the induction and occurrence of audiogenic seizures as a sign of withdrawal from GHB and 1,4-BD in selectively bred Sardinian alcohol-preferring (sP) rats, treated with escalating doses of GHB (1.5-3.5 g/kg, twice daily; i.g.) or 1,4-BD (500-1000 mg/kg, twice daily; i.g.) for 9 consecutive days. Acute administration of the selective GABAB receptor antagonist, SCH 50911, dramatically increased seizure occurrence. We propose that the inherent sensitivity of sP rats to different GHB-associated responses may have contributed to the unraveling of a phenomenon which was otherwise not recognizable in other rat strains.
Keywords
Related Topics
Life Sciences
Neuroscience
Neuroscience (General)
Authors
Mauro A.M. Carai, Lawrence S. Quang, Sergio Atzeri, Carla Lobina, Paola Maccioni, Alessandro Orrù, Gian Luigi Gessa, Timothy J. Maher, Giancarlo Colombo,